Nytyka (Nintedanib)

Nytyka is a tyrosine kinase inhibitor used in fibrotic lung disease and certain lung cancers.

• Idiopathic pulmonary fibrosis: slows disease progression and preserves lung function.
• Systemic sclerosis‑associated interstitial lung disease: reduces decline in forced vital capacity.
• Non‑small cell lung cancer: used in combination therapy to inhibit tumor growth and angiogenesis.

• Nintedanib blocks multiple receptor tyrosine kinases—including vascular endothelial growth factor receptors (VEGFR 1‑3), platelet‑derived growth factor receptors (PDGFR‑α/β), and fibroblast growth factor receptors (FGFR 1‑3). By inhibiting these pathways, it reduces fibroblast proliferation, angiogenesis, and extracellular matrix deposition, thereby limiting fibrotic remodeling and tumor vascularization.

Common Side Effects

• Diarrhea: frequent loose stools, often mild to moderate.
• Nausea: feeling of sickness, may be accompanied by loss of appetite.
• Vomiting: occasional episodes, usually related to gastrointestinal irritation.
• Abdominal pain: cramping or discomfort in the stomach area.
• Decreased appetite: reduced desire to eat, potentially leading to weight loss.
• Elevated liver enzymes: mild increases in ALT/AST observed in routine labs.

Serious or Rare Side Effects

• Hepatic failure: severe liver injury requiring medical attention.
• Major bleeding events: gastrointestinal or intracranial hemorrhage.
• Arterial thromboembolism: clot formation in arteries causing ischemia.
• Intestinal perforation: rare but life‑threatening bowel rupture.
• Severe hypertension: marked increase in blood pressure.
• Pneumonitis: inflammatory lung reaction presenting with cough and dyspnea.

Before initiating Nytyka, clinicians should assess baseline organ function and risk factors.

• Liver function monitoring: check ALT/AST and bilirubin regularly during therapy.
• Bleeding risk assessment: evaluate for anticoagulant use or coagulopathy.
• Cardiovascular evaluation: monitor blood pressure and manage pre‑existing hypertension.
• Renal impairment caution: adjust use in severe kidney disease.
• Pregnancy and lactation: avoid use due to unknown safety; discuss contraception.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Nytyka may interact with several drug classes; careful review is required.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase nintedanib exposure.
• Potent P‑gp/BCRP inhibitors (e.g., verapamil): can raise plasma concentrations.
• Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• Moderate P‑gp inhibitors (e.g., amiodarone): require dose observation.
• NSAIDs or antiplatelet agents: monitor for additive bleeding tendencies.